Total Payments
$157,760
2022 Payments
$1,484
Companies
6
Transactions
30
Medicare Patients
1,414
Medicare Billing
$83,594
Payment Breakdown by Category
Research$131,000 (83.0%)
Consulting$24,300 (15.4%)
Other$2,300 (1.5%)
Food & Beverage$160.12 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $131,000 | 16 | 83.0% |
| Consulting Fee | $24,300 | 10 | 15.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,300 | 1 | 1.5% |
| Food and Beverage | $160.12 | 3 | 0.1% |
Payments by Type
Research
$131,000
16 transactions
General
$26,760
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $131,000 | 16 | $0 (2021) |
| PFIZER INC. | $22,900 | 9 | $0 (2021) |
| Boehringer Ingelheim RCV GmbH & Co KG | $3,700 | 2 | $0 (2022) |
| Intercept Pharmaceuticals, Inc. | $76.20 | 1 | $0 (2020) |
| Seagen Inc. | $65.00 | 1 | $0 (2022) |
| LEICA MICROSYSTEMS INC. | $18.92 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $1,484 | 3 | Boehringer Ingelheim RCV GmbH & Co KG ($1,400) |
| 2021 | $127,900 | 11 | ABBVIE INC. ($114,000) |
| 2020 | $21,976 | 8 | AbbVie Inc. ($15,500) |
| 2019 | $6,200 | 7 | PFIZER INC. ($4,700) |
| 2018 | $200.00 | 1 | PFIZER INC. ($200.00) |
All Payment Transactions
30 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/09/2022 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $65.00 | General |
| 06/15/2022 | LEICA MICROSYSTEMS INC. | HistoCore SPECTRA ST (Device) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: Devices | ||||||
| 01/28/2022 | Boehringer Ingelheim RCV GmbH & Co KG | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 11/04/2021 | ABBVIE INC. | RINVOQ (Biological) | — | Cash or cash equivalent | $22,500.00 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy • Category: IMMUNOLOGY | ||||||
| 11/04/2021 | ABBVIE INC. | RINVOQ (Biological) | — | Cash or cash equivalent | $11,400.00 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Conventional and/or Biologic Therapies • Category: IMMUNOLOGY | ||||||
| 11/04/2021 | ABBVIE INC. | RINVOQ (Biological) | — | Cash or cash equivalent | $3,900.00 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433 • Category: IMMUNOLOGY | ||||||
| 07/29/2021 | ABBVIE INC. | SKYRIZI (Biological) | — | Cash or cash equivalent | $22,500.00 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohns Disease Who Failed Prior Biologic Treatment • Category: IMMUNOLOGY | ||||||
| 07/29/2021 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,300.00 | General |
| 05/05/2021 | ABBVIE INC. | SKYRIZI (Biological) | — | Cash or cash equivalent | $44,400.00 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis • Category: IMMUNOLOGY | ||||||
| 05/05/2021 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $9,200.00 | General |
| 05/05/2021 | ABBVIE INC. | SKYRIZI (Biological) | — | Cash or cash equivalent | $200.00 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis • Category: IMMUNOLOGY | ||||||
| 01/31/2021 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 01/28/2021 | ABBVIE INC. | SKYRIZI (Biological) | — | Cash or cash equivalent | $8,400.00 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis • Category: IMMUNOLOGY | ||||||
| 01/28/2021 | ABBVIE INC. | SKYRIZI (Biological) | — | Cash or cash equivalent | $700.00 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis • Category: IMMUNOLOGY | ||||||
| 06/30/2020 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $4,100.00 | General |
| 04/21/2020 | AbbVie Inc. | RINVOQ (Drug) | — | Cash or cash equivalent | $3,900.00 | Research |
| Study: M14-431 • Category: IMMUNOLOGY | ||||||
| 04/21/2020 | Boehringer Ingelheim RCV GmbH & Co KG | Pipeline (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,300.00 | General |
| 04/21/2020 | AbbVie Inc. | RINVOQ (Drug) | — | Cash or cash equivalent | $1,500.00 | Research |
| Study: M14-433 • Category: IMMUNOLOGY | ||||||
| 03/05/2020 | Intercept Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $76.20 | General |
| 01/20/2020 | AbbVie Inc. | SKYRIZI (Biological) | — | Cash or cash equivalent | $8,300.00 | Research |
| Study: M16-067 • Category: IMMUNOLOGY | ||||||
| 01/20/2020 | AbbVie Inc. | RINVOQ (Drug) | — | Cash or cash equivalent | $1,200.00 | Research |
| Study: M14-431 • Category: IMMUNOLOGY | ||||||
| 01/20/2020 | AbbVie Inc. | RINVOQ (Drug) | — | Cash or cash equivalent | $600.00 | Research |
| Study: M14-433 • Category: IMMUNOLOGY | ||||||
| 10/23/2019 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| 10/23/2019 | AbbVie, Inc. | Rinvoq (Biological) | — | Cash or cash equivalent | $300.00 | Research |
| Study: M14-433 • Category: Immunology | ||||||
| 07/22/2019 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis | ABBVIE INC. | $45,100 | 2 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy | ABBVIE INC. | $22,500 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohns Disease Who Failed Prior Biologic Treatment | ABBVIE INC. | $22,500 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Conventional and/or Biologic Therapies | ABBVIE INC. | $11,400 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis | ABBVIE INC. | $8,600 | 2 |
| M16-067 | AbbVie Inc. | $8,300 | 1 |
| M14-431 | AbbVie Inc. | $5,100 | 2 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433 | ABBVIE INC. | $3,900 | 1 |
| M14-433 | AbbVie Inc. | $2,100 | 2 |
| M14-433 | AbbVie, Inc. | $1,200 | 2 |
| M14-431 | AbbVie, Inc. | $300.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 3 | 147 | 341 | $47,839 | $11,152 |
| 2021 | 9 | 309 | 579 | $69,239 | $16,008 |
| 2020 | 8 | 958 | 1,892 | $407,522 | $56,435 |
Total Patients
1,414
Total Services
2,812
Medicare Billing
$83,594
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2022 | 117 | 303 | $39,897 | $9,227 | 23.1% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2022 | 13 | 20 | $5,620 | $1,394 | 24.8% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Facility | 2022 | 17 | 18 | $2,322 | $530.65 | 22.9% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2021 | 139 | 317 | $40,422 | $9,408 | 23.3% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2021 | 26 | 33 | $10,668 | $2,340 | 21.9% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Facility | 2021 | 14 | 44 | $3,510 | $1,065 | 30.3% |
| 88331 | Pathology examination of specimen during surgery, first tissue block | Facility | 2021 | 15 | 19 | $2,128 | $1,012 | 47.6% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Facility | 2021 | 25 | 33 | $4,587 | $929.44 | 20.3% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Facility | 2021 | 13 | 47 | $3,631 | $484.33 | 13.3% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Facility | 2021 | 31 | 39 | $3,006 | $379.45 | 12.6% |
| 88311 | Preparation of tissue for examination by removing any calcium present | Facility | 2021 | 31 | 31 | $749.00 | $329.22 | 44.0% |
| 88300 | Pathology examination of tissue using a microscope, limited examination | Facility | 2021 | 15 | 16 | $538.00 | $60.16 | 11.2% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2020 | 386 | 876 | $254,095 | $26,143 | 10.3% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2020 | 187 | 427 | $64,598 | $13,613 | 21.1% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Office | 2020 | 203 | 276 | $28,980 | $5,882 | 20.3% |
| 88309 | Pathology examination of tissue using a microscope, high complexity | Facility | 2020 | 15 | 23 | $16,984 | $2,944 | 17.3% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2020 | 34 | 39 | $16,952 | $2,819 | 16.6% |
| 88341 | Special stained specimen slides to examine tissue | Facility | 2020 | 25 | 100 | $12,173 | $2,262 | 18.6% |
| 88342 | Tissue or cell analysis by immunologic technique | Facility | 2020 | 36 | 41 | $6,600 | $1,236 | 18.7% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Facility | 2020 | 27 | 35 | $3,344 | $800.40 | 23.9% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Facility | 2020 | 13 | 39 | $1,521 | $398.47 | 26.2% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Facility | 2020 | 32 | 36 | $2,275 | $336.17 | 14.8% |
About Mark Valasek, MD PHD
Mark Valasek, MD PHD is a Anatomic Pathology & Clinical Pathology healthcare provider based in Bryan, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/22/2009. The National Provider Identifier (NPI) number assigned to this provider is 1588808448.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Mark Valasek, MD PHD has received a total of $157,760 in payments from pharmaceutical and medical device companies, with $1,484 received in 2022. These payments were reported across 30 transactions from 6 companies. The most common payment nature is "" ($131,000).
As a Medicare-enrolled provider, Valasek has provided services to 1,414 Medicare beneficiaries, totaling 2,812 services with total Medicare billing of $83,594. Data is available for 3 years (2020–2022), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Anatomic Pathology & Clinical Pathology
- Location Bryan, TX
- Active Since 04/22/2009
- Last Updated 11/03/2023
- Taxonomy Code 207ZP0102X
- Entity Type Individual
- NPI Number 1588808448
Products in Payments
- SKYRIZI (Biological) $84,500
- RINVOQ (Biological) $37,800
- RINVOQ (Drug) $7,200
- Pipeline (Drug) $2,300
- Rinvoq (Biological) $300.00
- HistoCore SPECTRA ST (Device) $18.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Anatomic Pathology & Clinical Pathology Doctors in Bryan
Dr. Christopher Bibb, M.d, M.D
Anatomic Pathology & Clinical Pathology — Payments: $928,645
Anatomic Pathology & Clinical Pathology $928,645
Dr. Shannon Keil, Md, MD
Anatomic Pathology & Clinical Pathology — Payments: $280.19
Anatomic Pathology & Clinical Pathology $280.19
Oscar Lazcano, M.d, M.D
Anatomic Pathology & Clinical Pathology — Payments: $171.15
Anatomic Pathology & Clinical Pathology $171.15
Marcela Jimenez, M.d, M.D
Anatomic Pathology & Clinical Pathology — Payments: $166.50
Anatomic Pathology & Clinical Pathology $166.50
Myra Wong, Md, MD
Anatomic Pathology & Clinical Pathology — Payments: $53.51
Anatomic Pathology & Clinical Pathology $53.51
Rania Cannaday, M.d, M.D
Anatomic Pathology & Clinical Pathology — Payments: $31.87
Anatomic Pathology & Clinical Pathology $31.87